As such, FAP has been used as a co-target to deliver the T cell co-stimulatory 4-1BB ligand selectively to the tumour thereby circumventing systemic side effects of 4-1BB ligand such as cytokine release syndrome (93) (Figure 2D). This evidence concerns the gene TNFRSF9 and neoplasm.